Cannabinoids in intestinal inflammation and cancer

Angelo A. Izzo, Michael Camilleri

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer. Adaptive changes of the endocannabinoid system have been observed in intestinal biopsies from patients with inflammatory bowel disease and colon cancer. Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids - via direct or indirect activation of CB 1 and/or CB 2 receptors - exert protective effects in well-established models of intestinal inflammation and colon cancer. Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalPharmacological Research
Volume60
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

Intestinal Neoplasms
Cannabinoids
Colonic Neoplasms
Endocannabinoids
Inflammation
Inflammatory Bowel Diseases
Wound Healing
Epithelial Cells
Pharmacology
Cytokines
Biopsy

Keywords

  • Acylethanolamides
  • Anandamide
  • Apoptosis
  • Cannabidiol
  • Cannabinoid receptors
  • Colon cancer
  • Diarrhoea
  • Endocannabinoids
  • Fatty acid amide hydrolase
  • Gut
  • Inflammatory bowel disease
  • Intestinal motility
  • Phytocannabinoids
  • Prostamides
  • Visceral pain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cannabinoids in intestinal inflammation and cancer. / Izzo, Angelo A.; Camilleri, Michael.

In: Pharmacological Research, Vol. 60, No. 2, 08.2009, p. 117-125.

Research output: Contribution to journalArticle

@article{6f9bd0877b6744588490c9c5afad8c10,
title = "Cannabinoids in intestinal inflammation and cancer",
abstract = "Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer. Adaptive changes of the endocannabinoid system have been observed in intestinal biopsies from patients with inflammatory bowel disease and colon cancer. Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids - via direct or indirect activation of CB 1 and/or CB 2 receptors - exert protective effects in well-established models of intestinal inflammation and colon cancer. Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer.",
keywords = "Acylethanolamides, Anandamide, Apoptosis, Cannabidiol, Cannabinoid receptors, Colon cancer, Diarrhoea, Endocannabinoids, Fatty acid amide hydrolase, Gut, Inflammatory bowel disease, Intestinal motility, Phytocannabinoids, Prostamides, Visceral pain",
author = "Izzo, {Angelo A.} and Michael Camilleri",
year = "2009",
month = "8",
doi = "10.1016/j.phrs.2009.03.008",
language = "English (US)",
volume = "60",
pages = "117--125",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Cannabinoids in intestinal inflammation and cancer

AU - Izzo, Angelo A.

AU - Camilleri, Michael

PY - 2009/8

Y1 - 2009/8

N2 - Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer. Adaptive changes of the endocannabinoid system have been observed in intestinal biopsies from patients with inflammatory bowel disease and colon cancer. Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids - via direct or indirect activation of CB 1 and/or CB 2 receptors - exert protective effects in well-established models of intestinal inflammation and colon cancer. Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer.

AB - Emerging evidence suggests that cannabinoids may exert beneficial effects in intestinal inflammation and cancer. Adaptive changes of the endocannabinoid system have been observed in intestinal biopsies from patients with inflammatory bowel disease and colon cancer. Studies on epithelial cells have shown that cannabinoids exert antiproliferative, antimetastatic and apoptotic effects as well as reducing cytokine release and promoting wound healing. In vivo, cannabinoids - via direct or indirect activation of CB 1 and/or CB 2 receptors - exert protective effects in well-established models of intestinal inflammation and colon cancer. Pharmacological elevation of endocannabinoid levels may be a promising strategy to counteract intestinal inflammation and colon cancer.

KW - Acylethanolamides

KW - Anandamide

KW - Apoptosis

KW - Cannabidiol

KW - Cannabinoid receptors

KW - Colon cancer

KW - Diarrhoea

KW - Endocannabinoids

KW - Fatty acid amide hydrolase

KW - Gut

KW - Inflammatory bowel disease

KW - Intestinal motility

KW - Phytocannabinoids

KW - Prostamides

KW - Visceral pain

UR - http://www.scopus.com/inward/record.url?scp=67449135862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449135862&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2009.03.008

DO - 10.1016/j.phrs.2009.03.008

M3 - Article

VL - 60

SP - 117

EP - 125

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 2

ER -